ORCID as entered in ROS
https://orcid.org/0000-0002-4257-7620
Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Papers
, 2026, 'Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial', in Diabetologie und Stoffwechsel, Georg Thieme Verlag KG, presented at
, 2026, 'Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial', in Diabetologie und Stoffwechsel, Georg Thieme Verlag KG, presented at
, 2025, 'Biomarker Insights from the Phase 3 APPLAUSE-IgAN Study: Iptacopan's Proteomic Signature in IgAN', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'Discordance Between Cystatin C-Based eGFR and Creatinine-Based eGFR and Cardiovascular Risk in the FLOW Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'Effect of Semaglutide on Hemoglobin A1c and Body Weight Change by CKD Stage: Post Hoc Analysis from the FLOW Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'Effect of Semaglutide on Kidney Outcomes: Pooled Analysis of the SELECT, FLOW, and SOUL Trials', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'Efficacy and Safety of Iptacopan in Patients (Pts) from East Asia with IgAN: Interim Results from the Phase 3 APPLAUSE-IgAN Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'Glomerular Disease Registry and Biobank: Baseline and Follow-Up Results', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'Kidney, Cardiovascular, and Death Outcomes with Semaglutide Treatment Among Two Race and Two Ethnic Groups: Post Hoc Analysis from the FLOW Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, 'Risk of CKD Progression in a Real-World Population Eligible for the ZENITH-High Proteinuria Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, TX, Houston, presented at
, 2025, '1971-LB: Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial', in Diabetes, American Diabetes Association, http://dx.doi.org/10.2337/db25-1971-lb
, 2025, 'PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC
, 2024, 'Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, pp. E746 - E746, presented at
, 2024, 'Kidney, cardiovascular and all-cause mortality outcomes of semaglutide with and without baseline MRA use in type 2 diabetes and CKD: a FLOW trial analysis', in DIABETOLOGIA, SPRINGER, SPAIN, Madrid, pp. S519 - S519, presented at
, 2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, pp. 367 - 367, presented at
, 2023, 'A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ITALY, Milan, pp. I398 - I399, presented at
, 2023, 'HEART FAILURE IN ASCEND-ND AND ASCEND-D', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ITALY, Milan, pp. I453 - I455, presented at
, 2023, 'Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 678 - 678
, 2023, 'External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 418 - 419
, 2023, 'LONG-TERM SAFETY OF HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS', in NEPHROLOGY, WILEY, pp. 12 - 12
, 2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 367 - 367
, 2023, 'Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B1 - B1
, 2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 373 - 373
, 2023, 'Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial', in EUROPEAN JOURNAL OF HEART FAILURE, WILEY, pp. 177 - 178
, 2022, 'Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2022, 'Interleukin-6 and cardiovascular outcome in patients with type 2 diabetes: new insights from CANVAS', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, pp. S282 - S282, presented at
, 2022, 'BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, FRANCE, Paris, pp. I893 - I894, presented at
, 2022, 'A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 28 - 28
, 2022, 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 799 - 799
, 2022, 'Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2617 - 2617
, 2022, 'Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 1053 - 1053
, 2022, 'Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2621 - 2621
, 2022, 'Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 673 - 674
, 2022, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 33 - 34
, 2022, 'Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 116 - 116
, 2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 297 - 298
, 2022, 'On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 631 - 631
, 2021, 'Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial', in ARTHRITIS & RHEUMATOLOGY, WILEY, ELECTR NETWORK, pp. 1372 - 1373, presented at
, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2647 - 2647, http://dx.doi.org/10.26190/unsworks/28409
, 2021, 'ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, presented at
, 2021, 'Sglt2 inhibition for ckd and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation', in Diabetes, pp. 1 - 16, http://dx.doi.org/10.2337/dbi20-0040
, 2021, 'ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B2 - B3
, 2021, 'Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 47 - 47
, 2021, 'Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 263 - 264
, 2021, 'IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 190 - 190
, 2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 728 - 728
, 2021, 'The TESTING Study: Steroids vs. Placebo in High Risk IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B1 - B1
, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE KIDNEY FUNCTION: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Renoprotection with semaglutide and liraglutide: Direct or indirect effects?', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, pp. S67 - S68, presented at
Filter by type
https://orcid.org/0000-0002-4257-7620